高级检索
当前位置: 首页 > 详情页

Long Noncoding RNA LINC0086 Functions as a Tumor Suppressor in Nasopharyngeal Carcinoma by Targeting miR-214

文献详情

资源类型:
机构: [1]Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Dept Prevent Oncol, Guangzhou, Guangdong, Peoples R China; [2]Sun Yat Sen Univ, Sch Publ Hlth, Dept Med Stat & Epidemiol, Guangzhou, Guangdong, Peoples R China; [3]Cent S Univ, Xiangya Hosp 3, Dept Blood Transfus, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China
出处:
ISSN:

关键词: Nasopharyngeal carcinoma (NPC) Long noncoding RNAs (lncRNAs) LINC0086 miR-214 Carcinogenesis

摘要:
Nasopharyngeal carcinoma (NPC) is a distinct head and neck cancer, which is occurring at a high frequency in Southern China. Emerging studies have shown that long noncoding RNAs (lncRNAs) play a critical role in carcinogenesis and progression. In this study, we established a comprehensive lncRNA profile in NPC and found that 35 lncRNAs were differentially expressed in NPC. We found that LINC0086 was decreased in NPC patient serum samples and tissues. The Kaplan-Meier survival curve showed that patients with high LINC0086 expression had a higher survival rate than those with low LINC0086 expression. LINC0086 expression was associated with NPC histological grade, lymph node metastasis, and clinical stage. Upregulation of LINC0086 inhibited cancer cell proliferation and promoted apoptosis. In addition, upregulation of LINC0086 dramatically decreased the expression of miR-214, an oncogene in several cancers, in C666-1 and HK-1 cells. An miR-214 binding site was found in the 3'-UTR of LINC0086. We also validated that both miR-214 and LINC0086 presented in the RISC complex, demonstrating that LINC0086 could decrease miR-214 expression by directly interacting with miR-214. Furthermore, the suppressive effects of LINC0086 on NPC cell growth were reversed by overexpression of miR-214 in vitro and in vivo. Thus, our study reports a novel mechanism underlying NPC carcinogenesis and provides a potential novel diagnosis and treatment biomarker for NPC.

语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
第一作者:
第一作者机构: [1]Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Dept Prevent Oncol, Guangzhou, Guangdong, Peoples R China; [2]Sun Yat Sen Univ, Sch Publ Hlth, Dept Med Stat & Epidemiol, Guangzhou, Guangdong, Peoples R China;
通讯作者:
通讯机构: [3]Cent S Univ, Xiangya Hosp 3, Dept Blood Transfus, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy [2]Knockdown of long noncoding RNA GHET1 inhibits cell activation of gastric cancer [3]Knockdown of long noncoding RNA GHET1 inhibits cell activation of gastric cancer [4]10-Year Outcome on the Efficacy and Late Toxicities Attributed to the Addition of Concurrent-Adjuvant Chemotherapy for Stage IIII-VB Nasopharyngeal Carcinoma (Combined Analyses of the NPC-9901 and NPC-9902 Trials) [5]Identify the radiotherapy-induced abnormal changes in the patients with nasopharyngeal carcinoma [6]Assessment of self-reported financial toxicity among patients with nasopharyngeal carcinoma undergoing radiotherapy: A cross-sectional study in western China [7]Zinc Transporter 4 (ZIP4): A Predictive Biomarker for Decreasing Radiosensitivity and Promoting Tumor Migration and Metastasis Through TGF-beta-Dependent Manner in Nasopharyngeal Carcinoma (NPC) [8]Long-term result of a multicenter clinical study of cetuximab combined with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma (NPC). [9]An open, multicenter clinical study on cetuximab combined with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy in nasopharyngeal carcinoma (NPC): Preliminary report [10]A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT).

资源点击量:53699 今日访问量:0 总访问量:4607 更新日期:2025-02-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号